Radiotherapy with immunotherapy for NSCLC after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding radiotherapy (high-energy beams) to an immunotherapy drug (which helps the immune system fight cancer) works better than immunotherapy alone for people with non-small cell lung cancer that has spread to lymph nodes after surgery. It is for people who already had chemotherapy and immunotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have non-small cell lung cancer (a common type of lung cancer)
- Your cancer was stage IIIA or IIIB when first found, and you had chemotherapy plus an immunotherapy drug before surgery
- You had surgery to remove your lung cancer and the cancer was completely removed (no cancer cells at the edges)
- The cancer had spread to lymph nodes near your lungs (but not elsewhere) when tested after surgery
- You are generally well (able to do light activity) and your organs (blood, liver, kidneys) are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.